Literature DB >> 26783877

Trends in hematological cancer in the elderly in Denmark, 1980-2012.

Lukas F Ocias1, Thomas S Larsen1, Hanne Vestergaard1, Lone S Friis1, Niels Abildgaard1, Henrik Frederiksen1,2.   

Abstract

BACKGROUND: The number of hematological malignancies is expected to increase as the Danish population ages within the next few decades. Despite this, data on the course of hematological cancers among the oldest patients are sparse with many intervention studies focusing on younger age groups. The aim of this study is to present Danish incidence and mortality rates among older patients with non-Hodgkin lymphomas (NHL), multiple myeloma (MM), chronic lymphocytic leukemia (CLL), and acute myeloid leukemia (AML).
MATERIAL AND METHODS: Nationwide population-based study presenting the incidence, prevalence and mortality rates of NHL, MM, and AML with a focus on the elderly population in Denmark during the last few decades. Data were drawn from the NORDCAN database.
RESULTS: Incidence rates of NHL, MM, CLL and AML were 10-50 times higher among the population aged 70 years or more than among the younger population. An increasing incidence with stable or decreased mortality rates was seen mainly among elderly patients with NHL during the last few decades, leading to increased survival and a greater prevalence of patients with NHL. Increased relative survival and prevalence could also be seen among elderly patients with MM and CLL, while the trends of the incidence rates were inconclusive for these diseases. Survival among patients with AML improved most notably in those aged below 70 years leading to an increased prevalence of AML patients predominantly in this age group.
CONCLUSION: Improvements in diagnostics and treatment have led to increased survival and therefore prevalence of elderly patients with NHL, MM, CLL and AML during the past decades.

Entities:  

Mesh:

Year:  2016        PMID: 26783877     DOI: 10.3109/0284186X.2015.1115124

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  10 in total

Review 1.  Rapidly changing myeloma epidemiology in the general population: Increased incidence, older patients, and longer survival.

Authors:  Ingemar Turesson; Magnus Bjorkholm; Cecilie Hveding Blimark; Sigurdur Kristinsson; Ramon Velez; Ola Landgren
Journal:  Eur J Haematol       Date:  2018-04-20       Impact factor: 2.997

2.  Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO).

Authors:  Gabriele Nagel; D Weber; E Fromm; S Erhardt; M Lübbert; W Fiedler; T Kindler; J Krauter; P Brossart; A Kündgen; H R Salih; J Westermann; G Wulf; B Hertenstein; M Wattad; K Götze; D Kraemer; T Heinicke; M Girschikofsky; H G Derigs; H A Horst; C Rudolph; M Heuser; G Göhring; V Teleanu; L Bullinger; F Thol; V I Gaidzik; P Paschka; K Döhner; A Ganser; Hartmut Döhner; R F Schlenk
Journal:  Ann Hematol       Date:  2017-10-31       Impact factor: 3.673

3.  Evaluation of the Incidence of Hematologic Malignant Neoplasms Among Breast Cancer Survivors in France.

Authors:  Marie Joelle Jabagi; Norbert Vey; Anthony Goncalves; Thien Le Tri; Mahmoud Zureik; Rosemary Dray-Spira
Journal:  JAMA Netw Open       Date:  2019-01-04

4.  Clinical characteristics and outcomes among 2347 patients aged ≥85 years with major lymphoma subtypes: a Nordic Lymphoma Group study.

Authors:  Tove Wästerlid; Kim Oren Gradel; Sandra Eloranta; Ingrid Glimelius; Tarec C El-Galaly; Henrik Frederiksen; Karin E Smedby
Journal:  Br J Haematol       Date:  2020-11-24       Impact factor: 6.998

Review 5.  Patterns of undertreatment among patients with acute myeloid leukemia (AML): considerations for patients eligible for non-intensive chemotherapy (NIC).

Authors:  Elizabeth Hubscher; Slaven Sikirica; Timothy Bell; Andrew Brown; Verna Welch; Alexander Russell-Smith; Paul D'Amico
Journal:  J Cancer Res Clin Oncol       Date:  2021-08-30       Impact factor: 4.553

6.  Presence of the GFI1-36N single nucleotide polymorphism enhances the response of MLL-AF9 leukemic cells to CDK4/6 inhibition.

Authors:  Jan Vorwerk; Kaiyan Sun; Daria Frank; Felix Neumann; Jana Hüve; Paulina Marie Budde; Longlong Liu; Xiaoqing Xie; Pradeep Kumar Patnana; Helal Mohammed Mohammed Ahmed; Bertram Opalka; Georg Lenz; Ashok Kumar Jayavelu; Cyrus Khandanpour
Journal:  Front Oncol       Date:  2022-08-08       Impact factor: 5.738

7.  Caregivers of Patients with Hematological Malignancies within Home Care: A Phenomenological Study.

Authors:  Isabella Capodanno; Mirta Rocchi; Rossella Prandi; Cristina Pedroni; Enrica Tamagnini; Pierluigi Alfieri; Francesco Merli; Luca Ghirotto
Journal:  Int J Environ Res Public Health       Date:  2020-06-05       Impact factor: 3.390

8.  Increasing Incidence and Prevalence of Acquired Hemolytic Anemias in Denmark, 1980-2016.

Authors:  Dennis Lund Hansen; Sören Möller; Kjeld Andersen; David Gaist; Henrik Frederiksen
Journal:  Clin Epidemiol       Date:  2020-05-22       Impact factor: 4.790

9.  Incidence and Mortality Patterns of Acute Myeloid Leukemia in Belgrade, Serbia (1999⁻2013).

Authors:  Natasa Maksimovic; Milica Zaric; Tatjana Gazibara; Goran Trajkovic; Gorica Maric; Dragan Miljus; Nada Suvajdzic Vukovic; Dragica Tomin; Marijana Virijevic; Darija Kisic Tepavcevic; Tatjana Pekmezovic
Journal:  Medicina (Kaunas)       Date:  2018-03-20       Impact factor: 2.430

Review 10.  Indirect comparison of azacitidine and decitabine for the therapy of elderly patients with acute myeloid leukemia: a systematic review and network meta-analysis.

Authors:  Bingbing Wen; Weiwen You; Sitian Yang; Xin Du
Journal:  Exp Hematol Oncol       Date:  2020-03-16
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.